The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2018

Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2018

Publishing Date : Dec, 2018

License Type :
 

Report Code : 1376485

No of Pages : 129

Synopsis
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2018

Summary

clinical trial report, “Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2018" provides an overview of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned
Eli Lilly and Co
Cytori Therapeutics Inc
Sahajanand Medical Technologies Pvt Ltd
Mylan NV
Merck & Co Inc
Boston Scientific Corp
Bayer AG
AstraZeneca Plc
Amgen Inc
Abbott Laboratories

Geographical Area
Global
Index
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 16
Clinical Trials by Phase in G7 Countries 18
Clinical Trials in G7 Countries by Trial Status 19
Clinical Trials by E7 Countries: Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 21
Clinical Trials by Phase in E7 Countries 23
Clinical Trials in E7 Countries by Trial Status 24
Clinical Trials by Phase 26
In Progress Trials by Phase 27
Clinical Trials by Trial Status 28
Clinical Trials by End Point Status 29
Subjects Recruited Over a Period of Time 30
Clinical Trials by Sponsor Type 31
Prominent Sponsors 32
Top Companies Participating in Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials 34
Prominent Drugs 36
Clinical Trial Profile Snapshots 38
Appendix 127
Abbreviations 127
Definitions 127
Research Methodology 128
Secondary Research 128
About GlobalData 129
Contact Us 129
Source 129
List of Tables
List of Tables
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region, 2018* 7
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2018* 17
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 20
Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2018* 22
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 25
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase, 2018* 26
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 27
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 29
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 30
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 31
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 33
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 35
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 37

List of Figures
List of Figures
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 15
Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2018* 16
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 18
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 19
Proportion of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2018* 21
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 23
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 24
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 26
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 27
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 28
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 29
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 30
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 31
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 32
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 34
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 36
GlobalData Methodology 128

Published By : GlobalData

Why ‘The Market Reports’